Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees
Executive Summary
Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.